Posts

J&J Halts Phase 2a Rheumatoid Arthritis Program for Imaavy (Nipocalimab) after Lackluster Results

on

FDA Approves Updated COVID-19 Shots from Pfizer, Moderna, Novavax with New Restrictions

on

ESC25: GE HealthCare Showcases AI Cardiology Innovations for Earlier and More Accurate Diagnoses

on

Outlook Therapeutics Faces New FDA Setback for First Ophthalmic Avastin Formulation

on

Stockpiling Frenzy Prompts Lilly to Suspend UK Mounjaro Supply

on

Prothena's Alzheimer's Trial Hit by High ARIA-E Rates, Resulting in 'Non-Competitive' Profile

on

FDA Considers Noninvasive Endpoint for MASH Trials, Boosts Biotech Shares

on

Personalizing Metabolic Care with Digital Twins: Recent Developments

on

Vinay Prasad Explains FDA's Revocation of Pfizer's Covid Vaccine EUA for Children

on

Genentech's $700M North Carolina Plant and Telix’s FDA CRL Update

on

Exelixis to Lay Off 130 Employees, Shut Down Pennsylvania Site in Post-Pandemic Downsizing

on

Appia Bio Shuts Down Before Reaching Clinical Trials Amid Biotech Funding Crunch

on

Fosun Licenses Immunology Asset FXS6837 to Sitala in $670M Deal

on

Indivior Initiates Cost-Cutting Plan with Job Cuts and Real-Estate Review

on

Wugen Nabs $115M for Pivotal Study of Allogeneic CAR-T

on

Exelixis Closes Pennsylvania Site, Cuts 130 Jobs in Major Restructuring

on

Vinay Prasad Returns to the FDA With Fewer Titles and a Lower Profile

on

Sanofi Contributes to Report Emphasizing Importance of Sustainably Paid Community Health Workers

on

Eli Lilly Highlights Verzenio’s Survival Benefit Amid Novartis Competition in Early Breast Cancer

on

Amylyx Discontinues Rare Disease Program After Relyvrio Fails to Show Benefit Over Placebo

on

Hundreds of HHS Workers Accuse RFK Jr. of Destroying Public Health Trust After CDC Attack

on

CDC Staff and Medical Organization Liaisons Barred from New ACIP Covid-19 Working Group

on

Recent Advances: AI in Life Sciences—Reimagining Teams, Technology, and Partnerships

on

Who Is Making AI Work in Drug R&D in 2025?

on

Argenx's Vyvgart Shows Positive Phase 3 Results in Seronegative Myasthenia Gravis

on

Funding Drought Puts Pressure on Cell Therapy Startups Like Appia Bio

on

Akeso Scores Two Wins in Phase 3 Trials, Tees Up Regulatory Submissions in China

on

Novartis Pays $30M Upfront to Leqembi Creator BioArctic for Access to Blood-Brain Barrier Technology

on

Lilly to Seek Global Approval for GLP-1 Pill After Obesity and Diabetes Trial Success

on

Regeneron Reports Phase 3 Success for Cemdisiran in Rare Disease Generalized Myasthenia Gravis

on

AbbVie Buys Gilgamesh's Psychedelic Drug Bretisilocin for $1.2B

on

Akeso, Summit's PD-1xVEGF Drug Ivonescimab Shows Strong Progression-Free Survival Benefit in Global Lung Cancer Trial

on

Recent Advances for Confident Cell Line Transfer

on

Royalty Pharma Buys $885M Imdelltra Royalty Stake from BeOne

on

MannKind to Acquire scPharmaceuticals in Up to $360M Deal

on

Argenx Prepares FDA Filing to Expand Vyvgart Use in Myasthenia Gravis After Late-Stage Trial Win

on

CNS Pharmaceuticals Pursues Public Offering to Fund Phase 2 GBM Trial After Cost Cuts

on

FDA Begins Daily Publication of Drug Adverse Event Data

on

Resilience Through Reinvention: How Pharma is Navigating Uncertainty During Turbulent Times

on

Data Lakes & FAIR Principles: Making Scientific Data Accessible and Actionable

on

FDA Suspends Valneva's Chikungunya Vaccine, Ixchiq, Due to Serious Safety Concerns

on

UK Drugmakers and Government at Impasse Over New Medicine Rebate Scheme

on